AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03868709
Drug: Penehyclidine inhalation
RxNorm normalized name: Penequinine, Penehyclidine
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
Trial: NCT03783208
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
Trial: NCT00802802
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
Trial: NCT00802802
Drug: Rifampin-containing anti-TB therapy
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
Trial: NCT01166542
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Trial: NCT01166542
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
Trial: NCT02582970
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
Trial: NCT02582970
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
Trial: NCT02582970
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
Trial: NCT02582970
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
Trial: NCT00003237
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003237
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01188928
Drug: Calcipotriol plus betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical suspension once daily for up to 8 weeks.
Trial: NCT01188928
Drug: Betamethasone-17,21-dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical suspension once daily for up to 8 weeks.
Trial: NCT01188928
Drug: Calcipotriene
RxNorm normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical suspension once daily for up to 8 weeks.
Trial: NCT01188928
Drug: Topical suspension vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical suspension once daily for up to 8 weeks.
Trial: NCT03552757
Drug: Semaglutide 1.0 mg
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Trial: NCT03552757
Drug: Semaglutide 2.4 mg
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
Trial: NCT03298451
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (intravenous infusion).
Trial: NCT01431924
Drug: Higher-dose inhaled corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate 110 or 220 mcg
Trial: NCT01431924
Drug: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
Trial: NCT02570074
Drug: Fosfomycin
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Broad spectrum antibiotic
Trial: NCT03298451
Drug: Tremelimumab (Regimen 1)
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab IV (intravenous infusion).
Trial: NCT03298451
Drug: Tremelimumab (Regimen 2)
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab IV (intravenous infusion).
Trial: NCT03298451
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib, as per standard of care
Trial: NCT03298451
Drug: Durvalumab (Regimen 2)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab IV (intravenous infusion).
Trial: NCT00926328
Drug: Triclosan, fluoride
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six Month study, brush twice daily
Trial: NCT00926328
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice daily usage
Trial: NCT00639678
Drug: raxibacumab
RxNorm normalized name: Raxibacumab
DrugBank: Raxibacumab (DB08902)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 1
Trial: NCT03502668
Drug: ASTX727 LD
RxNorm normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral decitabine (LD) + cedazuridine (E7727)
Trial: NCT03502668
Drug: ASTX727 SD
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral decitabine (SD) + cedazuridine (E7727)
Trial: NCT03765632
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan is used for non-myeloablative conditioning
Trial: NCT03765632
Drug: Peg-Ada
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
Trial: NCT00639678
Drug: raxibacumab
RxNorm normalized name: Raxibacumab
DrugBank: Raxibacumab (DB08902)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40 mg/kg intravenously, single dose, day 0, Group 2
Trial: NCT04410328
Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
Trial: NCT01307098
Drug: Sebelipase alfa 0.35 mg/kg
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Trial: NCT01307098
Drug: Sebelipase alfa 1 mg/kg
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Trial: NCT01988883
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
Trial: NCT01988883
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
Trial: NCT01307098
Drug: Sebelipase alfa 3 mg/kg
DrugBank: Sebelipase alfa (DB11563)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Trial: NCT00982553
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800mg once daily
Trial: NCT00982553
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg twice daily
Trial: NCT00903396
Drug: palonosetron hydrochloride
RxNorm normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03119831
Drug: Alcohol-based Chlorhexidine Gluconate 0.12%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Trial: NCT03119831
Drug: Alcohol-free Chlorhexidine Gluconate 0.12%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Trial: NCT03119831
Drug: C31G
RxNorm normalized name: C31G
DrugBank: C31G (DB05398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with 15ml for one minute twice daily for 14 days
Trial: NCT04590235
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available.
Trial: NCT04308681
Drug: BMS-986278
RxNorm normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT02070549
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02304679
Drug: 1 month of PDE5i treatment
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg Tadalafil per day for 1 month
Trial: NCT03295721
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl without epinephrine, 50 mg by injection
Trial: NCT01920737
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
Trial: NCT01520051
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 monthly intravenous infusions of 750 mg
Trial: NCT01920737
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01920737
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01920737
Drug: PEG-Asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01920737
Drug: 6-MP (6-Mercaptopurine)
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01920737
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01282151
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
Trial: NCT01282151
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
Trial: NCT04524897
Drug: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
Trial: NCT00569881
Drug: gatifloxacin and moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of wound healing between drugs
Trial: NCT00194597
Drug: Viagra (sildenafil citrate)
RxNorm normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00388960
Drug: Amrubicin
RxNorm normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.
Trial: NCT00388960
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Trial: NCT00388960
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Trial: NCT00040365
Drug: Amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
Trial: NCT04360629
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid will be given through central vein
Trial: NCT01137695
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mcg SQ three times daily for 6 months.
Trial: NCT01137695
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 360 mcg SQ three times daily for 6 months
Trial: NCT01137695
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120 mcg SQ three times daily for 6 months
Trial: NCT00770510
Drug: Eszopiclone 1 mg
RxNorm normalized name: eszopiclone 1 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Trial: NCT00770510
Drug: Eszopiclone 2 mg
RxNorm normalized name: eszopiclone 2 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Trial: NCT00770510
Drug: Eszopiclone 3 mg
RxNorm normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Trial: NCT00770510
Drug: Zolpidem Tartrate 10 mg
RxNorm normalized name: zolpidem tartrate 10 MG
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
Trial: NCT00556049
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously on days 1 and 8 of each 21-day treatment cycle.
Trial: NCT00556049
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Orally on days 1-14 of each 21-day treatment cycle
Trial: NCT01920737
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00571428
Drug: Arformoterol Tartrate Inhalation Solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
Trial: NCT00571428
Drug: Arformoterol Tartrate Inhalation Solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
Trial: NCT01818856
Drug: Ritonavir withdrawal, atazanavir 200 mg/12h
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01818856
Drug: Telaprevir interactions
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02705820
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switch maintenance pembrolizumab treatment
Trial: NCT03048162
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 ml of 0.9% isotonic sodium chloride
Trial: NCT03048162
Drug: Hydroxyethylstarch
RxNorm normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 6% Hydroxyethylstarch
Trial: NCT03048162
Drug: Ringer-Lactate Infusion Solution Bag
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of Ringer-Lactate Infusion Solution Bag
Trial: NCT00526968
Drug: EVT 101
RxNorm normalized name: EVT-101
DrugBank: EVT-101 (DB05956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg capsule, single oral dose
Trial: NCT00526968
Drug: EVT 101
RxNorm normalized name: EVT-101
DrugBank: EVT-101 (DB05956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg capsule, single oral dose
Trial: NCT03164772
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PD-L1
Trial: NCT03164772
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CTLA-4
Trial: NCT02831569
Drug: Loxoprofen sodium
RxNorm normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02831569
Drug: Methocarbamol
RxNorm normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
FDA approved: yes
EMA approved: no
PMDA approved: no